Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Common Equity (2020 - 2025)

Historic Common Equity for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $335.1 million.

  • Tarsus Pharmaceuticals' Common Equity rose 4109.67% to $335.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.1 million, marking a year-over-year increase of 4109.67%. This contributed to the annual value of $224.5 million for FY2024, which is 1398.36% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Common Equity of $335.1 million as of Q3 2025, which was up 4109.67% from $332.6 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Common Equity ranged from a high of $342.5 million in Q1 2025 and a low of $147.7 million during Q2 2023
  • Moreover, its 5-year median value for Common Equity was $202.6 million (2022), whereas its average is $222.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 240248.81% in 2021, then tumbled by 3330.67% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Common Equity (Quarter) stood at $166.7 million in 2021, then grew by 15.7% to $192.9 million in 2022, then grew by 2.12% to $197.0 million in 2023, then grew by 13.98% to $224.5 million in 2024, then soared by 49.23% to $335.1 million in 2025.
  • Its Common Equity stands at $335.1 million for Q3 2025, versus $332.6 million for Q2 2025 and $342.5 million for Q1 2025.